High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer

Frank M. Scott, Rama Modali, Teresa A. Lehman, Michael Seddon, Karen Kelly, Edward C. Dempsey, Vincent Wilson, Melvyn S. Tockman, James L. Mulshine

Research output: Contribution to journalArticle

34 Scopus citations

Abstract

A high frequency of K-ras mutations may indicate preneoplastic changes in the bronchial epithelium as a result of genotoxic injury. With the use of sensitive detection techniques, we report a higher prevalence of K-ras mutations in bronchoalveolar lavage than has been reported previously for lung cancer. A PCR/ligase chain reaction technique was used to determine K-ras codon 12 mutations in a group of 52 bronchoalveolar lavage specimens from patients at risk of a second lung cancer. Of the specimens examined, 84% contained at least one mutation in K-ras codon 12, corroborated by an allele-specific hybridization method. These results suggest that point mutations in K-ras codon 12 are widespread in the bronchial epithelium. Based on these preliminary findings, further evaluation of this efficient sensitive assay to monitor K-ras status should be conducted in larger clinical cohorts where clinical outcomes will ultimately be available. Such a trial will define the utility of K-ras codon 12 mutation status as a marker of lung cancer.

Original languageEnglish (US)
Pages (from-to)479-482
Number of pages4
JournalClinical Cancer Research
Volume3
Issue number3
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Scott, F. M., Modali, R., Lehman, T. A., Seddon, M., Kelly, K., Dempsey, E. C., Wilson, V., Tockman, M. S., & Mulshine, J. L. (1997). High frequency of K-ras codon 12 mutations in bronchoalveolar lavage fluid of patients at high risk for second primary lung cancer. Clinical Cancer Research, 3(3), 479-482.